Singapore markets closed
  • Straits Times Index

    3,294.86
    +0.04 (+0.00%)
     
  • Nikkei

    27,522.26
    -250.67 (-0.90%)
     
  • Hang Seng

    24,965.55
    +13.20 (+0.05%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • BTC-USD

    38,546.04
    -4,689.23 (-10.85%)
     
  • CMC Crypto 200

    905.83
    +663.15 (+273.26%)
     
  • S&P 500

    4,443.93
    -38.80 (-0.87%)
     
  • Dow

    34,552.50
    -162.89 (-0.47%)
     
  • Nasdaq

    13,962.69
    -191.33 (-1.35%)
     
  • Gold

    1,833.00
    -9.60 (-0.52%)
     
  • Crude Oil

    84.96
    -0.59 (-0.69%)
     
  • 10-Yr Bond

    1.7530
    -0.0800 (-4.36%)
     
  • FTSE Bursa Malaysia

    1,527.06
    -0.69 (-0.05%)
     
  • Jakarta Composite Index

    6,726.37
    +99.50 (+1.50%)
     
  • PSE Index

    7,293.52
    +54.24 (+0.75%)
     

X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market Opportunities for Mavorixafor

  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • XFOR

Company to present new clinical data supporting the expanded potential use of mavorixafor to treat a broad array of immunodeficiencies as well as new insights into WHIM syndrome

Guest speakers include thought leaders with expertise in the research and
treatment of rare immunodeficiencies

Webcast to take place following ASH Annual Meeting on December 16, 2021 at 8:30 a.m. EST

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with immune system dysfunction, today announced that it will host a virtual seminar “Understanding Primary Immunodeficiencies” on Thursday, December 16, 2021 at 8:30 a.m. EST to discuss new clinical data on mavorixafor, X4’s late-stage clinical candidate, and new research data being presented at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting. As previously announced, X4 will be hosting four poster presentations at ASH, which is taking place in Atlanta, Georgia, and virtually December 11-14, 2021.

The event will feature presentations from X4 senior management and the following thought leaders, experts in the research and treatment of rare immunodeficiencies:

  • Neal Sondheimer, M.D., Ph.D., clinical and research geneticist at the University of Toronto and Head of Metabolic Medicine at SickKids Hospital. His clinical work focuses on inherited metabolic disorders, while his research focuses on rare disease discovery and the impact of sequence variation in the mitochondrial genome on disease presentation.

  • Theresa Tarrant, M.D., Associate Professor of Medicine, Rheumatology, and Immunology at the Duke University School of Medicine, where she focuses on understanding why and how autoimmunity and immune deficiency disorders develop. A practicing clinician, her research investigates immune targets that may either impact the development of immune disease or help identify new therapies for patients.

Webcast Details
X4 Virtual Seminar “Understanding Primary Immunodeficiencies”
Date: Thursday, December 16, 2021
Time: 8:30 a.m. EST
Link to webcast

A live webcast will be available on the investors section of the X4 Pharmaceuticals’ website at www.x4pharma.com. Following the live webcast, the event will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days. Participants may also access the audio portion of the presentation by dialing (866) 721-7655 in the US, or (409) 216-0009 internationally, citing the following conference ID: 6995899.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies to benefit people with immune system dysfunction. The company’s lead candidate is mavorixafor, a first-in-class, small molecule antagonist of chemokine receptor CXCR4 that is being developed as a once-daily oral therapy. Due to mavorixafor’s ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells, X4 believes that mavorixafor has the potential to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Mavorixafor has already demonstrated clinical potential in a Phase 2 trial in people with WHIM syndrome, a rare PID. Its efficacy and safety continue to be evaluated in a global Phase 3 clinical trial in WHIM (fully enrolled) and in two Phase 1b clinical trials – one, as monotherapy in people with Severe Congenital Neutropenia (SCN) and other chronic neutropenia conditions, and another in combination with ibrutinib in people with Waldenström’s macroglobulinemia, a rare B-cell lymphoma. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, to discover and develop additional product candidates. For more information, please visit www.x4pharma.com.

Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, statements regarding the clinical development and therapeutic potential of mavorixafor; X4’s potential growth and evolution; and the advancement of X4’s pipeline. Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development; the risk that trials and studies may be delayed, including, but not limited to, as a result of the effects of the ongoing COVID-19 pandemic or delayed patient enrollment, and may not have satisfactory outcomes; the risk that the outcomes of preclinical studies or earlier clinical trials will not be predictive of later clinical trial results; the potential adverse effects arising from the testing or use of mavorixafor or other product candidates; risks related to X4’s ability to raise additional capital and other risks and uncertainties, including those described in the section entitled “Risk Factors” in X4’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 4, 2021, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

Contacts:
Glenn Schulman, PharmD, MPH (corporate)
VP, Investor Relations & Corporate Communications
glenn.schulman@x4pharma.com
(203) 494-7411

Daniel Ferry (investors)
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Mónica Rouco Molina (media)
Senior Account Executive, LifeSci Communications
mroucomolina@lifescicomms.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting